KPW
EPZM

Kore Private Wealth’s Epizyme, Inc EPZM Stock Holding History

Kore Private Wealth’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,000
Closed -$16K – 1172
2020
Q2 		$16K Hold
1,000
– – ﹤0.01% 700
2020
Q1 		$16K Hold
1,000
– – ﹤0.01% 624
2019
Q4 		$25K Buy
+1,000
New +$14.8K ﹤0.01% 596
2019
Q2 		– Sell
-1,000
Closed -$12K – 839
2019
Q1 		$12K Buy
+1,000
New +$11.2K ﹤0.01% 610

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Kore Private Wealth's EPZM Position: Q3 2020 in Review

Kore Private Wealth sold out of Epizyme, Inc (EPZM) in Q3 2020, closing a stake of 1,000 shares — an estimated $16K sold.

Kore Private Wealth first reported a position in EPZM in Q1 2019 and held it in 4 quarters. The position peaked at $25K in Q4 2019. 151 funds tracked by Wall St. Rank hold EPZM as of Q3 2020.

  • Kore Private Wealth reported no remaining Epizyme, Inc position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 1,000 Epizyme, Inc shares in Q3 2020, an estimated $16K.
  • Kore Private Wealth first reported a position in Epizyme, Inc in Q1 2019 and held it in 4 quarters.
  • Kore Private Wealth's Epizyme, Inc position peaked at $25K in Q4 2019.
  • 151 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.